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http://dx.doi.org/10.1016/j.pedneo.2Dexamethasone is widely used in preterm infants with severe pulmonary disease. Hypertrophic
cardiomyopathy (HCM) is a transient side effect observed after multiple doses of dexametha-
sone. We report a preterm infant with myocardial hypertrophy after a single dose of dexa-
methasone (0.5 mg/kg) used to treat laryngeal edema secondary to prolonged intubation. A
benign course was observed without left ventricular outflow tract obstruction and with recov-
ery within 4 weeks. Myocardial effects of dexamethasone may be independent of dose and
duration of treatment. The risk/benefit ratio must be carefully considered before using even
a single dose of dexamethasone in preterm infants.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Glucocorticoids, in particular dexamethasone, are widely
used in preterm infants with severe lung disease to facili-
tate weaning from the ventilator, and in the prophylaxis
and treatment of bronchopulmonary dysplasia (BPD).1e3Intensive Care Unit, Etlik
hing and Research Hospital,
kara, Turkey.
.com.tr (O. Aydemir).
an Pediatric Association. Publish
013.03.015However, glucocorticoids are associated with numerous
adverse effects such as gastrointestinal hemorrhage, hy-
perglycemia, hypertension, hypertrophic cardiomyopathy
(HCM), adrenal suppression, increased risk of sepsis, psy-
chomotor development delay, and cerebral palsy.3,4 HCM is
commonly reported in infants after multiple doses of
dexamethasone.5e7 It has been shown that frequency and
severity of myocardial hypertrophy increase with dose and
duration of treatment.8,9 Herein, we present a preterm
infant with transient myocardial hypertrophy after a single
dose of dexamethasone used to treat laryngeal edema
secondary to prolonged intubation.ed by Elsevier Taiwan LLC. All rights reserved.
Figure 2 Echocardiography showing normal interventicular
septum (IVS) thickness 4 weeks after treatment with a single
dose of dexamethasone.
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A 1500-g male infant was born at 32 weeks’ gestation to a 17-
year-old primigravida by vaginal delivery. A single dose of
betamethasone was given to the mother just an hour before
delivery. Apgar scoreswere 4 and8 at 1minuteand5minutes,
respectively. The patient was intubated in the delivery room
andadmitted to theneonatal intensive care unit. He received
two doses of surfactant for respiratory distress syndrome. On
day 5, a systolicmurmur was noted and a pediatric cardiology
consultation was requested. Echocardiography revealed
patent foramen ovale and minimal ductal shunt. The thick-
ness of the interventricular septum (IVS) was normal at that
time. Every attempt at extubation failed with worsening re-
tractions over time. The patient was placed on a mechanical
ventilator until day10.A stridorwasaudible uponextubation,
suggesting upper airway obstruction, and the vocal cords
appeared edematous on direct laryngoscopy. A single dose of
dexamethasone 0.5 mg/kg was given intravenously. The pa-
tient tolerated extubation and was followed on nasal
continuous positive airway pressure for an additional 4 days
and weaned to supplemental oxygen thereafter. On day 16,
echocardiography was repeated because of a worsening sys-
tolic ejectionmurmur. Echocardiographic evaluation showed
marked thickening of the IVS (6 mm) and mild thickening of
the posterior left ventricular wall without outflow tract
obstruction (Figure 1). Prenatal history was reevaluated for
factors causing HCM. A maternal oral glucose tolerance test
was normal, and drug history was unremarkable. The
maternal glycatedhemoglobin (HbA1c) levelwas 5.2%. Serum
biochemistry, blood gases, and tandem mass spectroscopy
analysis were normal. Serial echocardiograms were per-
formedweekly. Maximal thickness of the IVSwas 7mmonday
23 and progressively decreased to 3 mm on day 44 (Figure 2).
The baby was completely asymptomatic all the time. Sup-
plemental oxygen was discontinued on the 30th day, and he
was discharged on the 45th postnatal day. At post-discharge
follow-up, cardiologic evaluation was normal.
3. Discussion
HCM is defined as septal or posterior wall thickness that is
more than two standard deviations above the mean normalFigure 1 Echocardiography showing interventricular septum
thickening (IVSd Z 0.6 cm) (blue lines) 6 days after a single
dose of dexamethasone.thickness measured by echocardiography.10 Myocardial hy-
pertrophy can be encountered in infants with maternal
diabetes,11 in utero ritodrine exposure,12 perinatal
asphyxia,13 several metabolic diseases,14e16 Noonan syn-
drome,17 systemic hypertension, and familial HCM caused
by mutations in genes encoding sarcomeric proteins.18 In
our case, prenatal history was negative for maternal risk
factors as well as the familial history regarding genetic and
metabolic diseases. Betamethasone was started just before
birth to induce lung maturity in this infant and only a single
dose was given. It has been shown that a single or repeated
course of prenatal corticosteroids does not alter myocardial
thickness in preterm infants.19,20 The maternal oral glucose
tolerance test in pregnancy and the postpartum HbA1c
level were in the normal range in our patient. Furthermore,
echocardiography performed on the 5th day of life revealed
normal IVS and left ventricular thickness, which means
prenatal and maternal causes could not be responsible for
the observed myocardial hypertrophy. Our patient did not
have any clinical and laboratory evidence of metabolic and
genetic disorders. The reversible nature of myocardial hy-
pertrophy makes metabolic and familial causes very
unlikely.
HCM secondary to dexamethasone therapy is usually a
benign conditionwith spontaneous recovery 2e5weeks after
discontinuation.8 Rarely, symptomatic left ventricular
outflow tract obstruction may be observed.21,22 Why dexa-
methasone induces myocardial thickening and which dose
and duration are safe remain unclear. At a cellular level,
cardiac hypertrophy usually results from hypertrophy of
myocytes by the synthesis of various intracellular cardiac
proteins.23 Thedensities of insulin-like growth factor 1 (IGF1)
and insulin receptors are highest in the neonatal period and
decrease during infancy. An effect of dexamethasone
through IGF1 or its receptors on cardiac myocytes may
explain dexamethasone-induced left ventricular hypertro-
phy. A greater degree of hypertrophy is observed in infants
receiving insulin in addition to the dexamethasone.8 Dexa-
methasone schedules for prevention and treatment of BPD
have changed over time in an attempt to find the lowest
possible doses with adequate therapeutic effect and to limit
adverse reactions. Zecca et al reported that even a low dose
and short course (1 week) therapy with dexamethasone can
270 Y. Kale et alhave adverse cardiac effects.7 This is the first report of HCM
in a preterm infant after a single dose of dexamethasone.
Hypertrophy was more prominent in the IVS than the left
ventricular wall, which returned to normal within 4 weeks. A
benign course was observed without left ventricular outflow
tract obstruction. The infant had no symptoms related to
myocardial hypertrophy.
In conclusion, even a single dose of dexamethasone may
produce a transient myocardial hypertrophy in preterm
infants. Risks and benefits should be considered while using
dexamethasone in preterm infants with the possible addi-
tional risk of HCM.References
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